Skip to main content
NIH funding notice RFA-DE-24-005

Developing Salivary Components as Therapeutics for Oral Health (R21 Clinical Trial Not Allowed)

Closed on November 22, 2023.

Posted
August 29, 2023
Close date
November 22, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $196,875 in first-year total cost, median $196,875.

Most frequent study sections

  1. Special Emphasis Panel[ZDE1 AC (15)]1

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA LOS ANGELES1
Competing awards under RFA-DE-24-005 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024The function role of salivary piRNAs in oral wound healing1R21DE034146-01LI, FENGUNIVERSITY OF CALIFORNIA LOS ANGELES, CA$196,875ZDE1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DE-24-005: Developing Salivary Components as Therapeutics for Oral Health (R21 Clinical Trial Not Allowed) | ScienceDex | ConductScience